Skip to main content
Log in

Phenotyping cost effective in reducing risk of myelosuppression

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2018 euros

Reference

  • Zarca K, et al. Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis. Molecular Diagnosis and Therapy : 8 Apr 2019. Available from: URL: http://doi.org/10.1007/s40291-019-00398-x

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phenotyping cost effective in reducing risk of myelosuppression. PharmacoEcon Outcomes News 826, 20 (2019). https://doi.org/10.1007/s40274-019-5822-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5822-9

Navigation